Janus Haagensen1, Davide Verotta2, Liusheng Huang3, Joanne Engel4, Alfred M Spormann5, Katherine Yang3. 1. Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs Lyngby, Denmark. 2. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco School of Pharmacy, San Francisco, CA 94143, USA. 3. Department of Clinical Pharmacy, University of California San Francisco School of Pharmacy, San Francisco, CA 94143, USA. 4. Departments of Medicine and Microbiology/Immunology, University of California San Francisco, San Francisco, CA 94143, USA. 5. Department of Civil and Environmental Engineering, James H. Clark Center, Stanford University, Stanford, CA 94305, USA.
Abstract
OBJECTIVES: The selection and dose of antibiotic therapy for biofilm-related infections are based on traditional pharmacokinetic studies using planktonic bacteria. The objective of this study was to characterize the time course and spatial activity of human exposure levels of meropenem and tobramycin against Pseudomonas aeruginosa biofilms grown in an in vitro flow-chamber model. METHODS: Pharmacokinetic profiles of meropenem and tobramycin used in human therapy were administered to GFP-labelled P. aeruginosa PAO1 grown in flow chambers for 24 or 72 h. Images were acquired using confocal laser scanning microscopy throughout antibiotic treatment. Bacterial biomass was measured using COMSTAT and pharmacokinetic/pharmacodynamic models were fitted using NONMEM7. RESULTS: Meropenem treatment resulted in more rapid and sustained killing of both the 24 and 72 h PAO1 biofilm compared with tobramycin. Biofilm regrowth after antibiotic treatment occurred fastest with tobramycin. Meropenem preferentially killed subpopulations within the mushroom cap of the biofilms, regardless of biofilm maturity. The spatial killing by tobramycin varied with biofilm maturity. A tobramycin-treated 24 h biofilm resulted in live and dead cells detaching from the biofilm, while treatment of a 72 h biofilm preferentially killed subpopulations on the periphery of the mushroom stalk. Regrowth occurred primarily on the mushroom caps. Combination meropenem and tobramycin therapy resulted in rapid and efficient killing of biofilm cells, with a spatial pattern similar to meropenem alone. CONCLUSIONS: Simulated human concentrations of meropenem and tobramycin in young and mature PAO1 biofilms exhibited differences in temporal and spatial patterns of killing and antibiotic tolerance development.
OBJECTIVES: The selection and dose of antibiotic therapy for biofilm-related infections are based on traditional pharmacokinetic studies using planktonic bacteria. The objective of this study was to characterize the time course and spatial activity of human exposure levels of meropenem and tobramycin against Pseudomonas aeruginosa biofilms grown in an in vitro flow-chamber model. METHODS: Pharmacokinetic profiles of meropenem and tobramycin used in human therapy were administered to GFP-labelled P. aeruginosa PAO1 grown in flow chambers for 24 or 72 h. Images were acquired using confocal laser scanning microscopy throughout antibiotic treatment. Bacterial biomass was measured using COMSTAT and pharmacokinetic/pharmacodynamic models were fitted using NONMEM7. RESULTS: Meropenem treatment resulted in more rapid and sustained killing of both the 24 and 72 h PAO1 biofilm compared with tobramycin. Biofilm regrowth after antibiotic treatment occurred fastest with tobramycin. Meropenem preferentially killed subpopulations within the mushroom cap of the biofilms, regardless of biofilm maturity. The spatial killing by tobramycin varied with biofilm maturity. A tobramycin-treated 24 h biofilm resulted in live and dead cells detaching from the biofilm, while treatment of a 72 h biofilm preferentially killed subpopulations on the periphery of the mushroom stalk. Regrowth occurred primarily on the mushroom caps. Combination meropenem and tobramycin therapy resulted in rapid and efficient killing of biofilm cells, with a spatial pattern similar to meropenem alone. CONCLUSIONS: Simulated human concentrations of meropenem and tobramycin in young and mature PAO1 biofilms exhibited differences in temporal and spatial patterns of killing and antibiotic tolerance development.
Authors: Joshua D Shrout; David L Chopp; Collin L Just; Morten Hentzer; Michael Givskov; Matthew R Parsek Journal: Mol Microbiol Date: 2006-10-24 Impact factor: 3.501
Authors: Kerry S Williamson; Lee A Richards; Ailyn C Perez-Osorio; Betsey Pitts; Kathleen McInnerney; Philip S Stewart; Michael J Franklin Journal: J Bacteriol Date: 2012-02-17 Impact factor: 3.490
Authors: Jeffrey A Bailey; Katherine S Virgo; Joseph T DiPiro; Avery B Nathens; Robert G Sawyer; John E Mazuski Journal: Surg Infect (Larchmt) Date: 2002 Impact factor: 2.150
Authors: Alba Ribera; Eva Benavent; Cristina El-Haj; Joan Gomez-Junyent; Fe Tubau; Raul Rigo-Bonnin; Javier Ariza; Oscar Murillo Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191
Authors: M V Sheraton; J K H Yam; C H Tan; H S Oh; E Mancini; L Yang; S A Rice; P M A Sloot Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Jules D P Valentin; Hervé Straub; Franziska Pietsch; Marion Lemare; Christian H Ahrens; Frank Schreiber; Jeremy S Webb; Henny C van der Mei; Qun Ren Journal: ISME J Date: 2021-12-08 Impact factor: 10.302